FutureMeds, with high traditional and DCT readiness across the whole network and home nursing solutions in 16 countries, is the 1st European Dedicated DCT Site Network. FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help speed up drug development and patient access to new treatments. Through acquisitions and a strategic focus on patient experience, FutureMeds has developed large, qualified patient pools across Europe that enable faster patient enrolment, stronger retention and more accurate results. FutureMeds has arisen from the leadership team’s passion for Clinical Research, their drive and their decades of experience building Dedicated Research Site networks across the globe. They previously created and scaled Synexus (now AES within PPD).
